Is Hepcidin a New Cardiovascular Risk Marker in Polycystic Ovary Syndrome?

Basit Öğe Kaydı
dc.authoridKaygusuz, Ikbal/0000-0002-5635-505X
dc.contributor.authorGozdemir, Elif
dc.contributor.authorKaygusuz, Ikbal
dc.contributor.authorKafali, Hasan
dc.date.accessioned2025-10-24T18:09:28Z
dc.date.available2025-10-24T18:09:28Z
dc.date.issued2013
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractBackground/Aims: Polycystic ovary syndrome (PCOS) is associated with reproductive and metabolic abnormalities and carries a number of cardiovascular risk factors. Low-grade chronic inflammation has been thought to play a role in the pathogenesis of atherosclerosis and PCOS patients have an increased rate of subclinical inflammation. In the present study, considering the major role that hepcidin plays in the regulation of iron metabolism and as an inflammatory marker, we investigated hepcidin in PCOS patients and its role in predicting cardiovascular disease (CVD) development. Methods: Forty patients with PCOS and 40 age- and body mass index-matched healthy controls were included in the study. Iron metabolites, insulin resistance (IR), inflammatory markers and hepcidin levels were analyzed. Results:IR parameters, inflammatory markers, iron parameters and hepcidin levels were similar between the PCOS and control groups. While the inflammatory markers were significantly high in the overweight and obese PCOS subgroup, the hepcidin levels were also high but this elevation was not statistically significant. Conclusion:Obesity is the principle mechanism of chronic inflammation and IR in PCOS patients. C-reactive protein and interleukin-6 should be used to predict and follow the risk of CVD development in PCOS cases. Hepcidin may be used as an additional marker in the follow-up of PCOS patients in the future. Copyright (C) 2013 S. Karger AG, Basel
dc.description.sponsorshipScientific Research Fund of Fatih University [P53010801-2]
dc.description.sponsorshipThis work was supported by the Scientific Research Fund of Fatih University under project number P53010801-2.
dc.identifier.doi10.1159/000348497
dc.identifier.endpage202
dc.identifier.issn0378-7346
dc.identifier.issn1423-002X
dc.identifier.issue3
dc.identifier.pmid23548757
dc.identifier.scopus2-s2.0-84876794070
dc.identifier.scopusqualityQ2
dc.identifier.startpage196
dc.identifier.urihttps://doi.org/10.1159/000348497
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3662
dc.identifier.volume75
dc.identifier.wosWOS:000317880400010
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherKarger
dc.relation.ispartofGynecologic And Obstetric Investigation
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjectPolycystic ovary syndrome; Hepcidin; Cardiovascular disease; Obesity; Insulin resistance
dc.titleIs Hepcidin a New Cardiovascular Risk Marker in Polycystic Ovary Syndrome?
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu